Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Copyright 2022, Business Wire.
news
2022-10-19 20:00:00

October 19, 2022 04:00 PM Eastern Daylight Time TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company's U.S. 11,459,351 patent (the â€˜351 patent) was granted by the U.S. Patent and Trademark Office. This patent strengthens the company's extensive portfolio protecting its use of dual-action keratolytic drug conjugates in development for the treatment of ocular diseases associated with the eye lid margin and Meibomian Gland Dysfunction (MGD).
